Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.23 HKD | -1.70% | -3.34% | +31.95% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.95% | 2.17B | - | ||
+25.61% | 672B | C+ | ||
+25.87% | 570B | B | ||
-5.24% | 360B | C+ | ||
+16.49% | 321B | B- | ||
+8.28% | 300B | C+ | ||
+7.09% | 217B | B+ | ||
-9.12% | 204B | A+ | ||
+5.01% | 199B | B- | ||
-8.75% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3933 Stock
- Ratings The United Laboratories International Holdings Limited